News & Updates

Children with early-onset atopic dermatitis (AD) are at increased odds of developing atopic march conditions compared with those with early-onset AD, reveals a study.

The biosimilar BAT2206 demonstrates similar efficacy, safety, pharmacokinetics, and immunogenicity to its reference drug, ustekinumab (UST), in a recent phase III trial.

A recent review integrates multiple research findings and turns the spotlight on the growing nephrotoxic threat posed by skin-whitening creams.

Treatment with remibrutinib, an oral, highly selective Bruton’s tyrosine kinase inhibitor, improved sleep and daily activities in patients with chronic spontaneous urticaria (CSU), according to two phase III REMIX-1 and -2 studies presented at AAD 2025.

Patients with palmoplantar pustulosis (PPP) treated with apremilast show improvements at week 16, with continued treatment resulting in maintained or further improvement at week 52, according to a study presented at AAD 2025. No new safety concerns have been observed.

Once-daily treatment with baricitinib resulted in clinically meaningful improvements in hair regrowth on the scalp, eyebrows, and eyelashes among adolescent patients with severe alopecia areata (AA), according to the BRAVE-AA-PEDS trial presented at AAD 2025.

The investigational anti–IL-23 monoclonal antibody QX004N appears to be well tolerated and have superior efficacy vs placebo in the treatment of patients with moderate to severe plaque psoriasis, according to a phase I study from China.